



ASX ANNOUNCEMENT

Lumos Signs Major Development and IP Agreements with Hologic

Highlights:

- Lumos Diagnostics (ASX:LDX) has signed two new Agreements with leading global women's health company, Hologic, Inc. (NASDAQ:HOLX).
- The Agreements include contracts for the development of, and intellectual property rights for, custom reader and point-of-care (POC) technologies.
- The IP Agreement has a value of US\$10M (non-refundable) payable to Lumos by the end of June 2024.
- The Development Agreement has a value of up to US\$4.7M which will be payable over the next 18-24 months dependent on the achievement of specified milestones.
- The Agreements represent a significant extension to an existing scope of work with Hologic, strengthens Lumos' balance sheet and provides a pipeline of revenue-generating partnerships in POC diagnostics.

MELBOURNE, Australia (11 January 2024) – Lumos Diagnostics Holdings Ltd (ASX:LDX, "Lumos" or the "Company") a leader in rapid, point-of-care (POC) diagnostic technologies, has today announced it has signed two new Agreements with US based women's health company, Hologic, Inc. (NASDAQ:HOLX).

Hologic is a leading innovator and diagnostics service provider in women's health and has engaged Lumos to develop a next generation version of one of Hologic's leading on-market women's health products.

The two Agreements ("Agreements") encompass a Development Agreement and an Intellectual Property ("IP") Agreement. Under the Development Agreement Lumos is entitled to receive up to US\$4.7 million in payments over an 18-24 month timeframe, subject to achieving certain development milestones. The IP Agreement provides Hologic with an exclusive license in the field of fetal fibronectin to Lumos proprietary reader and POC technologies that will be incorporated into the next generation product under development. This Agreement provides for two non-refundable US\$5.0 million payments to Lumos from Hologic, the first upon signing and the second in June 2024.

These Agreements build on previous contract development work conducted by Lumos for Hologic over the last 12-months. The new Agreements focus on the development of an improved version of one of Hologic's leading on market women's health products and includes adapting it for use on Lumos' proprietary reader platform.

Lumos Diagnostics CEO and MD, Doug Ward, said: *"We are delighted to further strengthen our strategic partnership with Hologic. These Agreements will support the development of the next generation of one of Hologic's leading commercial products, together with long-term, mutually beneficial clinical and commercial progress for both parties."*

"This strategic partnership has highlighted the value of credible partners in supporting the translation of our unique, proprietary reader platform technology in frontline healthcare settings."

The Company plans to hold a webinar on Tuesday, 16 January 2024 (Australian Time), to provide further detail on the transaction. Details to access the webinar will be released to the market in the coming days.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 (0) 423 139 163

Investor Contact:

Barrie Lambert
Chief Financial Officer, Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598

For personal use only